Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
GSK plc reported a buyback transaction executed via BNP Paribas SA on 12 November 2025, purchasing 167,000 ordinary shares at a volume‑weighted average price of 1,813.49p (range 1,805.50p–1,827.00p). The shares will be held as treasury shares and form part of the company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 8,663,000 shares. Following this transaction, GSK holds 256,127,844 shares in treasury and has 4,059,300,530 shares in issue (excluding treasury). The total number of voting rights is 4,059,300,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc filed a Form 6‑K reporting its UK block listing six‑monthly return for the period from 1 May 2025 to 31 October 2025, detailing movements under three employee share plans.
Under the GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan, securities issued/allotted were 0, with a balance of unallotted securities of 115,518 at period end.
For the GlaxoSmithKline plc Share Save Plan 2012, securities issued/allotted were 134,547, leaving a balance of unallotted securities of 135,768 at period end.
For the GlaxoSmithKline plc Share Save Plan 2022, securities issued/allotted were 47,674, with a balance of unallotted securities of 904,117 at period end.
GSK plc reported share repurchases under its ongoing buyback. On 11 November 2025, the company bought 167,000 ordinary shares at prices between 1,791.50p and 1,825.00p, with a volume‑weighted average price of 1,807.35p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 8,496,000 shares.
Following these transactions, GSK holds 255,960,844 shares in treasury and has 4,059,467,530 shares in issue (excluding treasury shares). The total number of voting rights is 4,059,467,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc reported a buyback of 170,000 ordinary shares on 10 November 2025 under its existing programme via BNP Paribas SA. Prices ranged from 1,753.50p to 1,779.00p per share, with a volume‑weighted average price of 1,768.72p.
Since 30 September 2025, GSK has purchased 8,329,000 ordinary shares. After this purchase, GSK holds 255,793,844 shares in treasury and has 4,059,634,530 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,634,530, and the percentage of voting rights attributable to treasury shares is 6.30%. Trades were executed on the London Stock Exchange and Cboe Europe order books.
GSK published provisional 2026 dividend timetable; dates are indicative and may change.
Q1: announce April 29, ex-div May 14 (ADS May 15), record May 15, DRIP June 18, payable July 9. Q2: announce July 29, ex-div August 13 (ADS August 14), record August 14, DRIP September 17, payable October 8. Q3: announce October 28, ex-div November 12 (ADS November 13), record November 13, DRIP December 14, payable January 7, 2027. Q4: announce February 3, 2027, ex-div February 18 (ADS February 19), record February 19, DRIP March 16, payable April 8, 2027.
GSK repurchased 170,000 ordinary shares on 07 November 2025 at a volume‑weighted average price of 1,772.64p (low 1,757.50p; high 1,788.50p) under its existing buyback programme via BNP Paribas SA. The shares will be held as treasury shares.
Since 30 September 2025, GSK has bought 8,159,000 shares. Following this transaction, it holds 255,623,844 shares in treasury and has 4,059,804,530 shares in issue (excluding treasury). Total voting rights are 4,059,804,530, and treasury shares represent 6.30% of voting rights.
GSK plc reported a buyback transaction executed through BNP Paribas SA, purchasing 170,000 ordinary shares on 06 November 2025 at a volume‑weighted average price of 1,778.72p (range: 1,769.50p–1,786.00p). The shares will be held as treasury shares and the trade forms part of the existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 7,989,000 shares.
After this purchase, GSK holds 255,453,844 shares in treasury and has 4,059,969,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,969,755, and the percentage of voting rights attributable to treasury shares is 6.29%.
FAQ
What is the current stock price of GSK PLC (GLAXF)?
